Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
An overview of situations where market-cap weighted benchmarks are appropriate and practical tips for effective performance comparison.
28,411 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
Unpack the essentials of fulgent genetics (flgt) earnings in plain language. This guide translates the earnings trans...
If you want steady income and long-term growth, these five dividend stocks right now combine durable dividends with s...
Investors are watching Lyft’s 2026 earnings closely to see if core growth, cost discipline, and smarter incentives ca...
Memory-chip demand has surged with AI and cloud growth, but timing still matters. This guide breaks down how to evalu...
As Neogen gears up for Q3 2026 earnings, investors are digging for signals beyond the headline numbers. This article ...
A new nonprofit research lab launched by five former Ethereum Foundation researchers aims to make Ethereum the settle...
A doctored AI image sparked laughter and questions about authenticity. This piece uses the moment to teach practical ...
ASML delivered a powerhouse quarter that suggests AI infrastructure spending remains resilient. With Intel set to rep...
A high-flying AI infrastructure stock surged 176% in a single year. This guide breaks down what powered that move, wh...
A major filming pause on secret lives mormon wives reveals how volatile reality TV income can be. This guide breaks d...
Sui Group's Q1 2026 results shed light on the company’s momentum and future path. This analysis breaks down the numbe...